Natriuretic Peptides for the Treatment of Heart Failure

Heart Failure: Pharmacologic Management

Volumn , Issue , 2007, Pages 154-173

  Sackner Bernstein, Jonathan D ^a   Skopicki, Hal ^a   Aaronson, Keith D ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

B type natriuretic peptide; Diuretic; Heart failure; Natriuretic peptides; Nitroglycerin

Indexed keywords

EID: 34250323189     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470994740.ch11     Document Type: Chapter

References (138)

1. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002;23:1861-1866.
2. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999;100:999-1008.
3. Lucas C, Johnson W, Hamilton M et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:840-847.
4. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
5. Packer M, Gottlieb SS, Kessler PD. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia. Am J Med 1986;80:23-29.
6. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 1992;19:II26-29.
7. Monrad E, Baim D, Smith H, Lanoue A. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986;73:III168-174.
8. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patientswith coronary artery disease and heart failure. Circulation 1987;76:577-584.
9. Dies F, Krell MJ, Whitlow P et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74:II-38 (Abstract).
10. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
11. Silver MA, Maisel A, Yancy CW et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:1-30
12. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94
13. de Bold AJ, Flynn TG. Cardionatrin I-a novel heart peptide with potent diuretic and natriuretic properties. Life Sci 1983;33:297-302.
14. Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 1983;117:859-865.
15. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
16. Hosoda K, Nakao K, Mukoyama M et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991;17: 1152-1155.
17. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
18. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-870.
19. Suga S, Nakao K, Itoh H et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of 'vascular natriuretic peptide system'. J Clin Invest 1992;90:1145-1149.
20. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC, Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992;263:H1318-H1321.
21. Suga S, Nakao K, Hosoda K et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130:229-239.
22. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081-1088.
23. Maack T, Suzuki M, Almeida FA et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675-678.
24. Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T. Atrial natriuretic factor-a circulating hormone stimulated by volume loading. Nature 1985;314:264-266.
25. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992;44: 479-602.
26. Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991;60:229-255.
27. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-832.
28. Tsuruda T, Boerrigter G, Huntley BK et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-1134.
29. Wei CM, Heublein DM, Perrella MA et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-1009.
30. Akioka K, Takeuchi K, Yanagi S et al. Prognostic value of Doppler transmittal flow patterns and cardiac natriuretic peptides in patients with chronic congestive heart failure admitted for episodes of acute decompensation. Heart Vessels 2000;15:53-60.
31. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-1941.
32. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86: 21-26.
33. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391.
34. Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-138.
35. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
36. Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-641
37. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
38. Sonnenberg JL, Sakane Y, Jeng AY et al. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 1988;9:173-180.
39. Wilkins MR, Unwin RJ, Kenny AJ. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993;43:273-285.
40. Good JM, Peters M, Wilkins M, Jackson N, Oakley CM, Cleland JG. Renal response to candoxatrilat in patients with heart failure. J AmColl Cardiol 1995;25:1273-1281.
41. Kimmelstiel CD, Perrone R, Kilcoyne L et al. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology 1996;87:46-53.
42. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998;351:1657-1658.
43. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-620.
44. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the OmapatrilatVersus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-926.
45. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111.
46. Coats AJ. Omapatrilat-the story of Overture and Octave. Int J Cardiol 2002;86:1-4.
47. Richards AM, Nicholls MG, Ikram H, Webster MW, Yandle TG, Espiner EA. Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985;1:545-549.
48. Tikkanen I, Fyhrquist F, Metsarinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985;2:66-69.
49. Cody RJ, Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-1374.
50. Holmes SJ, Espiner EA, Richards AM, YandleTG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-96
51. van der Zander K, Houben AJ, Hofstra L, Kroon AA, de Leeuw PW. Hemodynamic and renal effects of lowdose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2003;285:H1206-H1212.
52. Mattingly MT, Clavell AL, Brandt RR, Wei CM, Barclay PL, Burnett JC, Jr. Potentiation of the renal actions of canine brain natriuretic peptide by neutral endopeptidase inhibition. Am J Hypertens 1994;7:14A (Abstract).
53. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291:83-88.
54. NDA 20-920 Cardio-renal advisory committee briefing document (3749B2_01_Scios-1999.pdf). US FDA, 1999. http://www.fda.gov/cder/audiences/acspage/cardiovascularmeetings1. htm. (Accessed 28 September 2001)
55. Natrecor product insert. 2001. http://www.natrecor.com/919_Revised_Promotional_PI.pdf. (Accessed 25 August 2002)
56. Schreiner GF, Protter AA. B-type natriuretic peptide for the treatment of congestive heart failure. Curr Opin Pharmacol 2002;2:142-147.
57. Kudo T, Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 1984;312:756-757.
58. Akabane S, Matsushima Y, Matsuo H, Kawamura M, Imanishi M, Omae T. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic salineinfused kidney. Eur J Pharmacol 1991;198:143-148.
59. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-1588.
60. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
61. Hayashi M, TsutamotoT, WadaAet al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-1826.
62. Colucci WS, Elkayam U, Horton D et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
63. Publication Committee for the VMAC Investigators (Vasodilation in theManagement of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
64. Panel of Cardiology Experts Provides Recommendations to Scios Regarding NATRECOR, press release from Scios Inc., 13 June 2005. Scios Inc., 2005. http://www.sciosinc.com/scios/pr_1118721302. (Accessed 22 June 2005)
65. Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-3189.
66. Mills R, TH L, Horton D. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34: 155-162.
67. 3749b2_02_01-FDA-Combined Medical & Statistical Review.pdf. US FDA, 1999. http://www.fda.gov/cder/audiences/acspage/cardiovascularmeetings1.htm. (Accessed 28 September 2001)
68. Nieminen MS. Pharmacological options for acute heart failure syndromes: current treatments and unmet needs. Eur Heart J 2005;7:B20-B4.
69. 3749b2_02_02-FDA-Medical Review.pdf, NDA 20-920. US FDA, 2001. http://www.fda.gov/cder/audiences/acspage/cardiovascularmeetings1.htm. (Accessed 28 September 2001)
70. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-2701.
71. Kuga H, Ogawa K, Oida A et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 2003;67:443-448.
72. Asakura M, Jiyoong K, Minamino T, Shintani Y, AsanumaH, Kitakaze M. Rationale and design of a largescale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for STsegment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage byANP(J-WIND-ANP). Circ J 2004;68:95-100.
73. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patientswith left ventricular systolic dysfunction. J Card Fail 2002;8(6 Suppl):S465-71.
74. Tamura N, Ogawa Y, Chusho H et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-4244.
75. Hama N, Itoh H, Shirakami G et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acutemyocardial infarction. Circulation 1995;92:1558-1564.
76. Kawakami R, Saito Y, Kishimoto I et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acutemyocardial infarction. Circulation 2004;110:3306-3312.
77. Kikuchi M, Nakamura M, Suzuki T, Sato M, Takino T, Hiramori K. Usefulness of carperitide for the treatment of refractory heart failure due to severe acutemyocardial infarction. Jpn Heart J 2001;42:271-280.
78. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 2002;90:435-438.
79. Abramson BL, Ando S, Notarius CF, Rongen GA, Floras JS. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation 1999;99:1810-1815.
80. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-1227.
81. Meyer DJ, Jr., Huxley VH. Differential sensitivity of exchange vessel hydraulic conductivity to atrial natriuretic peptide. Am J Physiol 1990;258:H521-H528.
82. Rutlen DL, Christensen G, Helgesen KG, Ilebekk A. Influence of atrial natriuretic factor on intravascular volume displacement in pigs. Am J Physiol 1990;259:H1595-H1600.
83. Drazner M, McGuire DK, de Lemos JA. Nesiritide in acute heart failure. Lancet 2003;362:998-999.
84. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994;72: 226-230.
85. Lubsen J, Just H, Hjalmarsson AC et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results fromthe Pimobendan inCongestive Heart Failure (PICO) trial. Heart 1996;76:223-231.
86. Hampton JR, van Veldhuisen DJ, Kleber FX et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-977.
87. Cohn JN, Goldstein SO, Greenberg BH et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339: 1810-1816.
88. NDA 20-920: cardiovascular and renal drugs advisory committee briefing document (3749b2_01_Scios.pdf). Scios, 2001. http://www.fda.gov/cder/audiences/acspage/cardiovascularmeetings1.htm. (Accessed 25August 2001)
89. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144: 1102-1108.
90. Azevedo ER, Newton GE, ParkerAB, Floras JS, Parker JD. Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure. J Cardiovasc Pharmacol 2000;35:129-135.
91. McCullough PA, Soman SS, Shah SS et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-684.
92. Gibson CM, Pinto DS, Murphy SA et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535-1543.
93. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003;24:412-420.
94. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-348.
95. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann InternMed 1998;128:194-203.
96. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presentingwith acute coronary syndromes. Am J Cardiol 2003;92:509-514.
97. Nakayama Y, Sakata R, Ura M, Itoh T. Long-termresults of coronary artery bypass grafting in patients with renal insufficiency. Ann Thorac Surg 2003;75:496-500.
98. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
99. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
100. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009.
101. Mahon NG, Blackstone EH, Francis GS, Starling RC, 3rd, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002;40:1106-1113.
102. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
103. Krumholz HM, Chen YT, Vaccarino V et al. Correlates and impact on outcomes of worsening renal function in patients≥65 years of age with heart failure. AmJ Cardiol 2000;85:1110-1113.
104. Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-338.
105. Smith GL, Vaccarino V, Kosiborod M et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13-25.
106. Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141.
107. Aronson D, Horton D, Burger JJ. Prognostic significance of deteriorating renal function in patients with decompensated heart failure. JACC 2004;43:180A.
108. Butler J, Emerman C, Peacock WF, Mathur VS, Young JB. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant 2004;19:391-399.
109. Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-1625.
110. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
111. Peacock W, Emerman C, Group PS. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients. J Am Coll Cardiol 2003;41:336A.
112. Sackner-Bernstein J, Kowalski M, Fox M. Is there risk associated with the use of nesiritide for acute heart failure? J Am Coll Cardiol 2003;41:161A.
113. Silver M, Horton D, Ghali J, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.
114. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
115. Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
116. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-762.
117. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
118. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
119. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
120. Topol EJ. Nesiritide-not verified. N Engl J Med 2005;353:113-116.
121. Yancy CW, Saltzberg MT, Berkowitz RL et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94:595-601.
122. Future Directions in the Management of Heart Failure: The FUSION Trials. WebMD, 2004. http://www.medscape.com/viewprogram/3530_pnt. (Accessed 27 July 2005)
123. Tsuneyoshi H, Nishina T, Nomoto T et al. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 2004;110:II174-II179.
124. Lisy O, Lainchbury JG, Leskinen H, Burnett JC, Jr. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001;37:1089-1094.
125. Khurana VG, Wijdicks EF, Heublein DM et al. A pilot study of dendroaspis natriuretic peptide in aneurysmal subarachnoid hemorrhage. Neurosurgery 2004;55:69-75.
126. Chen HH, Lainchbury JG, Burnett JC, Jr. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. JAmColl Cardiol 2002;40:1186-1191.
127. Bestle MH, Olsen NV, Christensen P, Jensen BV, Bie P. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol 1999;276(3 Pt 2):R684-95.
128. Hirsch JR, Meyer M, Magert HJ et al. cGMP-dependent and-independent inhibition of a K+ conductance by natriuretic peptides: molecular and functional studies in human proximal tubule cells. J Am Soc Nephrol 1999;10(3):472-80.
129. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 1992;22(10):662-9.
130. Forssmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol 1998;110(4): 335-57.
131. Allgren RL, Marbury TC, Rahman SN et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997;336(12):828-34.
132. Schmitt M, Gunaruwan P, Payne N et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol 2004;24(5):911-7.
133. Cohn JN, Goldstein SO, Greenberg BH et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339(25): 1810-6.
134. Torre-Amione G, Young JB, Colucci WS et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42(1):140-7.
135. Mehra MR. Acute decompensated heart failure treatment: optimizing patient outcomes. Medscape.com; 2005. http://www.medscape.com/viewprogram/4459_pnt (Accessed November 27, 2005).
136. Adams KF. Acute decompensated heart failure treatment: optimizing patient outcomes. Medscape.com; 2005. http://www.medscape.com/viewprogram/4459_pnt (Accessed November 27, 2005).
137. Yancy CW. Is nesiritide safe and effective for acute heart failure? Protagonist. HFSA Annual Scientific Sessions. Boca Raton, FL; September 20, 2005.
138. Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 2005;7(6):1070-5.